Premium
Hepatitis B core‐related antigen levels predict recurrence‐free survival in patients with HBV‐associated early‐stage hepatocellular carcinoma: results from a Dutch long‐term follow‐up study
Author(s) -
Beudeker Boris J. B.,
Groothuismink Zwier M. A.,
Man Robert A.,
Witjes Caroline D. M.,
Eijk Annemiek A.,
Boonstra Andre,
Sonneveld Milan J.
Publication year - 2021
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1111/jvh.13394
Subject(s) - hepatocellular carcinoma , medicine , stage (stratigraphy) , hepatitis b , gastroenterology , hepatitis b virus , oncology , immunology , virus , biology , paleontology
Prognosis of hepatitis B (HBV)‐associated hepatocellular carcinoma (HCC) is poor due to high rates of HCC recurrence and progression of underlying liver disease. We studied whether serum hepatitis B core‐related antigen (HBcrAg) levels could predict HCC recurrence and outcome in HBV associated. Higher HBcrAg levels at HCC diagnosis were independently associated with reduced overall and recurrence‐free survival in patients with early, but not advanced, stage HCC.